Methoxy polyethylene glycol-epoetin beta

Adult: Dosage is individualised and adjusted according to target Hb concentration. In patients who are not currently treated with an erythropoiesis stimulating agent (ESA): Patients not on dialysis: Initially, 1.2 mcg/kg once every month via single SC inj in the abdomen, arm or thigh. Alternatively, initiate at 0.6 mcg/kg once every 2 weeks via single SC inj (in the abdomen, arm or thigh) or IV inj. Patients on dialysis: Initially, 0.6 mcg/kg once every 2 weeks as a single SC inj (in the abdomen, arm or thigh) or IV inj. Doses may be adjusted by approx 25% at monthly intervals if needed. Maintenance dose: After reaching the target Hb concentration, administer once monthly using the dose equal to twice the previous once-every-2-week dose then subsequently titrate as necessary. In patients who are currently treated with an ESA (e.g. epoetin alfa or darbepoetin alfa): Initially, the dose is based on the total weekly dose of the previous ESA at the time of substitution. Inject the 1st dose at the next scheduled dose of the previously administered ESA. Administer once a month or once every 2 weeks as a single SC inj (in the abdomen, arm or thigh) or single IV inj. Doses may be adjusted by approx 25% at monthly intervals if needed and should not be adjusted more often than once every 4 weeks. Use the lowest necessary dose to reduce the need for RBC transfusions. Dosage recommendations may vary among individual products and between countries (refer to specific product guidelines).
Child: 3 months-17 years Dosage is individualised and adjusted according to target Hb concentration. In patients who are currently being treated with an ESA: Initially, the dose is based on the total weekly dose of the previous ESA at the time of substitution. Administer once every 4 weeks via IV or SC inj; maintain the same route of administration as the previous ESA. Doses may be adjusted by approx 25% if needed and should not be adjusted more often than once every 4 weeks. Use the lowest necessary dose to reduce the need for RBC transfusions. Dosage recommendations may vary among individual products and between countries (refer to specific product guidelines).